Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant

Summary

The purpose of this study is to evaluate whether fostamatinib, a drug that blocks activated B cells will be effective in preventing and treating chronic graft vs host disease (cGVHD) after allogeneic stem cell transplant. Activated B cells may play a role in development of cGVHD. Inhibiting the B cell activation using fostamatinib after allogeneic stem cell transplant may prevent the development of cGVHD.

Timeline

Start

2016-01

Primary completion

2021-02

Completion

2022-02-22

Drugs

Indications